
VIE
Healthcare · Biotechnology · $2.91B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2021
EPS trend, 90 days to now · +4.1% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 1, 2021 | Time not confirmed | -0.70 | -0.60 | +14.3% |
| Nov 10, 2020 | After the close | -0.76 | -0.69 | +9.4% |
| Aug 12, 2020 | After the close | -1.08 | -0.74 | +31.3% |
| May 13, 2020 | After the close | -0.73 | -0.80 | -9.1% |
| Mar 25, 2020 | After the close | -0.47 | -0.23 | +51.7% |
| Nov 14, 2019 | After the close | -2.27 | -1.17 | +48.6% |
Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder; and which is in Phase III trials for patients with myasthenia gravis and IgG4-related diseases, as well as…